Page last updated: 2024-12-10

3-amino-1-methyl-5h-pyrido(4,3-b)indole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-amino-1-methyl-5H-pyrido(4,3-b)indole: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5284476
CHEMBL ID365481
CHEBI ID34328
SCHEMBL ID894692
MeSH IDM0071327

Synonyms (40)

Synonym
BIDD:ER0587
brn 0647116
1-methyl-9h-pyrido(4,3-b)indol-3-amine
tryptophan p2
rp-p-2
3-amino-1-methyl-5h-pyrido(4,3-b)indole
trytophan pyrolysate 2
5h-pyrido(4,3-b)indol-3-amine, 1-methyl-
tryptophan-p-2
1-methyl-3-amino-5h-pyrido(4,3-b)indole
ccris 1415
5h-pyrido(4,3-b)indole, 3-amino-1-methyl-
3-amino-1-methyl-gamma-carboline
trp-2
1-methyl-5h-pyrido[4,3-b]indol-3-ylamine
bdbm50151132
72254-58-1
3-amino-1-methyl-5h-pyrido[4,3-b]indole
trp-p-2
62450-07-1
CHEMBL365481 ,
FT-0661942
1-methyl-5h-pyrido[4,3-b]indol-3-amine
(1-methyl-5h-pyrido[4,5-b]indol-3-yl)-amine
775uj9hctr ,
unii-775uj9hctr
3-amino-1-methyl-5h-pyrido[4,3-b]indolediscontinued see a618001
tryptophan p 2
FT-0614909
SCHEMBL894692
1-methyl-5h-pyrido(4,3-b)indol-3-amine
trp-p 2
3-amino-1-methyl-.gamma.-carboline
trp-p-2 [iarc]
DTXSID5043768
CHEBI:34328
trp-p2
1-methyl-5h-pyrido[3,4-b]indol-1-amine, 9ci
Q27115994
rac n'-nitrosonornicotine 5'-acetate

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" While the tryptophan pyrolysis product 3-amino-1,4-dimethyl-5H-pyrido[4,3-b]indole (Trp-P-1) and the mycotoxin sterigmatocystin were highly toxic to the cultures at moderate concentration (1 microgram/ml), the potency of each agent was increased > or = 10-fold in the presence of TCDD."( 2,3,7,8-Tetrachlorodibenzo-p-dioxin sensitization of cultured human epidermal cells to carcinogenic heterocyclic amine toxicity.
deGraffenried, LA; Rice, RH; Walsh, AA, 1995
)
0.29
" 6-Nitrochrysene, a known direct-acting mutagen in bacteria, was highly toxic to the rat but not to the human cells."( Cytotoxicity and keratinocyte microsome-mediated mutagenic activation of carcinogens in cultured epidermal cells.
Chun, HS; Kado, NY; Kuzmicky, PA; Rice, RH; Rucoba, L, 2000
)
0.31

Bioavailability

ExcerptReferenceRelevance
"The results suggest that (i) there is a decreased bioavailability of the Trp-P-2 in the majority of the tissues examined in bacteria supplemented mice and (ii) there is a low but distinct CYP1A-dependent activation of Trp-P-2 in the lung of BNF-treated mice."( Effects of lactic acid bacteria on the uptake and distribution of the food mutagen Trp-P-2 in mice.
Annas, A; Brittebo, EB; Nord, CE; Orrhage, KM; Rafter, JJ, 2002
)
0.31
" Finally, we demonstrated that the biological activity of Trp-P-1 and Trp-P-2 is strictly dependent on the presence of the mutagen in a free (unbound with methylxanthine) form, suggesting that mutagen sequestration in stacking heterocomplexes with methylxanthines can decrease its bioavailability and diminish its biological effects."( Caffeine and other methylxanthines as interceptors of food-borne aromatic mutagens: inhibition of Trp-P-1 and Trp-P-2 mutagenic activity.
Gołuński, G; Kaźmierkiewicz, R; Piosik, J; Woziwodzka, A; Wyrzykowski, D, 2013
)
0.39

Dosage Studied

ExcerptRelevanceReference
" The dose-response curve obtained was suitable for the determination of Trp-P-2 in the range of 20-800 pg."( Enzyme immunoassay for (3-amino-1-methyl-5H-pyrido[4,3-b]indole), a tryptophan pyrolysate.
Miyairi, S; Nambara, T, 1991
)
0.28
" Riboflavin decreased SCEs induced by Trp-P-2 in all treatment schedules, although statistically confirmed minima were observed in the dose-response curves, except in post-treatment experiments."( Effects of beta-carotene, retinal, riboflavin, alpha-tocopherol and vitamins C and K1 on sister-chromatid exchanges induced by 3-amino-1-methyl-5H-pyrido[4,3-b]indole (Trp-P-2) and cyclophosphamide in human lymphocyte cultures.
Dunkelberg, H; Edenharder, R; Kerkhoff, G, 1998
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
pyridoindole
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bifunctional dihydrofolate reductase-thymidylate synthasePlasmodium falciparum K1Ki2.30000.00000.43696.6645AID238767
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID238767Inhibition constant against Plasmodium falciparum dihydrofolate reductase2004Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17
Three-dimensional quantitative structure-activity relationship analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors using a pharmacophore generation approach.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (173)

TimeframeStudies, This Drug (%)All Drugs %
pre-199080 (46.24)18.7374
1990's64 (36.99)18.2507
2000's24 (13.87)29.6817
2010's5 (2.89)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 8.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index8.84 (24.57)
Research Supply Index5.24 (2.92)
Research Growth Index4.08 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (8.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (1.60%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other184 (98.40%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]